R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Senior Scientist 2 - Biophysics and Protein Sciences

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeRedwood City, CA, USA

About the Job

Requirements

  • Ph.D. in Biophysics, Biochemistry, Structural Biology, or a related discipline, with 8+ years of industry experience in drug discovery.
  • Demonstrated scientific judgment in experimental design and execution, data interpretation, and selecting appropriate orthogonal approaches to address challenging discovery questions.
  • Extensive hands-on experience in protein biochemistry and biophysics, including recombinant protein characterization and work with challenging proteins and multi-protein complexes.
  • Strong foundation in quantitative biophysical methods, with experience selecting and applying orthogonal approaches such as DSF, SEC-MALS, DLS, CD, ITC, SPR, and BLI to address complex discovery questions.
  • Experience supporting hit validation, mechanism-of-action studies, and structure-based drug discovery.
  • Ability to integrate biophysical data with medicinal chemistry, structural biology, and functional biology to guide project decisions.
  • Ability to work independently in a fast-paced discovery environment while contributing effectively as a collaborative team member.

Responsibilities

  • Serve as the biophysical subject matter expert on multidisciplinary discovery teams, providing scientific leadership that informs target validation, screening strategies, and lead optimization.
  • Design, execute, and interpret quantitative biophysical experiments to characterize protein quality, molecular interactions, binding mechanisms, kinetics, thermodynamics, stability, oligomerization, and higher-order complex formation, integrating these data to drive project decisions.
  • Develop and apply orthogonal biophysical strategies that accelerate hit confirmation, mechanistic understanding, and progression from screening hits to validated leads through early go/no-go decision making.
  • Build and optimize workflows to assess the quality, stability, and suitability of recombinant proteins and protein complexes, ensuring quality reagents for biochemical, biophysical, structural, and screening applications.
  • Characterize weak, transient, cooperative, and induced protein interactions using solution-based biophysics to complement structural biology and support mechanistic understanding of binary and ternary protein complexes.
  • Develop and implement robust biophysical assays, workflows, and best practices while evaluating emerging technologies that strengthen orthogonal hit validation and mechanistic discovery capabilities.
  • Evaluate emerging biophysical technologies and methodologies that enhance the organization's ability to address challenging discovery questions.
  • Communicate scientific findings effectively across multidisciplinary teams, provide technical mentorship, and promote rigorous experimental design and data-driven decision making.

Desired Qualifications

  • Experience with molecular glues, induced proximity, or complex protein–protein interaction systems, including analysis of ternary or higher-order complex formation and stability.
  • Familiarity with higher-order or structural biophysics methods such as SAXS, HDX-MS, and NMR to contextualize binding mechanisms and protein behavior in solution.
  • Experience establishing new biophysical technologies, workflows, and practices within a discovery organization.
  • Experience balancing internal experimentation with external CRO resources to solve complex scientific problems efficiently.
  • Track record of reducing technical risk through orthogonal experimental design and mechanistic problem solving.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs